The Mary M. Wohlford Laboratory for Male Contraceptive Research, Population Council, New York, NY 10065, USA.
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19623-8. doi: 10.1073/pnas.1111414108. Epub 2011 Nov 21.
The blood-testis barrier (BTB), one of the tightest blood-tissue barriers in the mammalian body, creates an immune-privileged site for postmeiotic spermatid development to avoid the production of antibodies against spermatid-specific antigens, many of which express transiently during spermiogenesis and spermiation. However, the BTB undergoes extensive restructuring at stage VIII of the epithelial cycle to facilitate the transit of preleptotene spermatocytes and to prepare for meiosis. This action thus prompted us to investigate whether this stage can be a physiological window for the delivery of therapeutic and/or contraceptive drugs across the BTB to exert their effects at the immune-privileged site. Herein, we report findings that P-glycoprotein, an ATP-dependent efflux drug transporter and an integrated component of the occludin/zonula occludens 1 (ZO-1) adhesion complex at the BTB, structurally interacted with focal adhesion kinase (FAK), creating the occludin/ZO-1/FAK/P-glycoprotein regulatory complex. Interestingly, a knockdown of P-glycoprotein by RNAi was found to impede Sertoli cell BTB function, making the tight junction (TJ) barrier "leaky." This effect was mediated by changes in the protein phosphorylation status of occludin via the action of FAK, thereby affecting the endocytic vesicle-mediated protein trafficking events that destabilized the TJ barrier. However, the silencing of P-glycoprotein, although capable of impeding drug transport across the BTB and TJ permeability barrier function, was not able to induce the BTB to be "freely" permeable to adjudin. These findings indicate that P-glycoprotein is involved in BTB restructuring during spermatogenesis but that P-glycoprotein-mediated restructuring does not "open up" the BTB to make it freely permeable to drugs.
血睾屏障(BTB)是哺乳动物体内最紧密的血液组织屏障之一,它为精母细胞后减数分裂期的发育创造了一个免疫特权部位,以避免针对精母细胞特异性抗原产生抗体,其中许多抗原在精子发生和精子排放过程中短暂表达。然而,BTB 在上皮细胞周期的第八阶段会经历广泛的重构,以促进预减数分裂精母细胞的转运,并为减数分裂做准备。因此,这一行为促使我们研究这个阶段是否可以成为一个生理窗口,通过该窗口可以将治疗性和/或避孕药物递送到 BTB 中,以在免疫特权部位发挥作用。在此,我们报告了以下发现:P-糖蛋白是一种 ATP 依赖性外排药物转运蛋白,也是 BTB 中紧密连接蛋白(occludin)/封闭蛋白(zonula occludens 1,ZO-1)黏附复合物的组成部分,它与粘着斑激酶(focal adhesion kinase,FAK)结构上相互作用,形成 occludin/ZO-1/FAK/P-糖蛋白调节复合物。有趣的是,通过 RNAi 敲低 P-糖蛋白被发现会阻碍支持细胞 BTB 功能,使紧密连接(TJ)屏障“渗漏”。这种效应是通过 FAK 作用于 occludin 的蛋白磷酸化状态来介导的,从而影响内吞小泡介导的蛋白运输事件,破坏 TJ 屏障的稳定性。然而,尽管沉默 P-糖蛋白能够阻碍药物穿过 BTB 和 TJ 通透性屏障的转运,但它不能诱导 BTB 对阿霉素(adjudin)变得“自由”通透。这些发现表明,P-糖蛋白参与精子发生过程中的 BTB 重构,但 P-糖蛋白介导的重构并不能“打开” BTB,使其对药物自由通透。